/
BYSI
$0.84-$0.16 (-15.78%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$30.5M
41M shares
52-week range
$0.73 – $2.44
6% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-21.23
BeyondSpring Inc. Ordinary Shares
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
www.beyondspringpharma.com- Employees
- 44
- IPO / List date
- Mar 9, 2017
- HQ
- FLORHAM PARK, NJ
Held by traders on TradeandTell
No one on the platform currently holds BYSI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 11,100 | $18.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BYSI yet.
